Skip to content
Screener

ANI Pharmaceuticals ANIP Total Liabilities & Equity

Total Liabilities & Equity at other companies

Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$3.78B+10.3%
Viatris logo
ViatrisVTRS
$35.04B-8.8%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$329.68M-21.9%
ALN
Alnylam PharmaceuticalsALNY
$5.56B+21.7%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$97.71M+16.3%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$792.26M+57.6%

Other financials

Income statement

See full
Revenue$266.0M+25.9%
Gross profit$165.9M+21.3%
Operating income$40.5M+191%
Net income$24.7M+189%
EPS (diluted)$1.05+192%

Balance sheet

See full
Cash & equivalents$360.2M+65.4%
Total debt$301.5M-4.2%
Total equity$597.2M+36.7%
Total assets$1.5B+11.3%

Cash flow

See full
Operating cash flow$56.7M-25.3%
CapEx$3.1M-23.9%
Free cash flow$53.6M-25.3%

Valuation

See full
Market cap$1.88B+25.6%
Enterprise value$1.82B+14.3%
P/E17.3×
P/S1.9×-0.1×

Profitability

See full
Gross margin60.4%-0.7pp
Operating margin15.4%
Net margin11.1%+10.0pp
FCF margin17.7%+0.9pp

Returns & leverage

See full
Return on equity21%+19.1pp
Debt / equity0.5×-0.2×
Current ratio2.9×+0.4×

Where this comes from

Reported directly by ANI Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: ANI Pharmaceuticals’s 10-Q, filed August 7, 2026.

Filed
Aug 7, 2026, 7:01 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001023024-26-000069
Line itemJune 30,2026December 31,2025
Class C Special Stock, $0.0001 par value, 781,281 shares authorized; 10,864 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively
Preferred Stock, $0.0001 par value, 1,666,667 shares authorized; 0 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively
Treasury stock, 891,915 shares of common stock, at cost, at June 30, 2026 and 621,296 shares of common stock, at cost, at December 31, 2025(53,817)(33,249)
Additional paid-in capital620,249596,036
Retained earnings (Accumulated deficit)31,104(23,099)
Accumulated other comprehensive (loss) income, net of tax(327)1,033
Total Stockholders’ Equity597,212540,724
Total Liabilities and Stockholders’ Equity$1,494,112$1,440,377

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is ANI Pharmaceuticals's total liabilities & equity?
ANI Pharmaceuticals (ANIP) reported total liabilities & equity of $1.49B in Q2 2026.
How has ANI Pharmaceuticals's total liabilities & equity changed year-over-year?
ANI Pharmaceuticals's total liabilities & equity increased by 11.3% year-over-year, from $1.34B to $1.49B.
What is the long-term trend for ANI Pharmaceuticals's total liabilities & equity?
Over 5 years (2020 to 2025), ANI Pharmaceuticals's total liabilities & equity has grown at a 25.6% compound annual growth rate (CAGR), from $461.19M to $1.44B.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about ANI Pharmaceuticals's total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude